MPB-1523

DB18334InvestigationalSmall molecule

MPB-1523 is a contrast agent comprising PEGylated iron oxide nanoparticles.

Code names
MPB 1523

What you can answer from here — as of September 19, 2023

1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of MPB-1523, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In